EPICS Therapeutics appoints Elisabeth Svanberg as new member of its Board of Directors

Published: 19.09.2023

Gosselies, Belgium September 18th, 2023

Elisabeth Svanberg MD, PhD is Associated Professor of Surgery at University of Gothenburg, Sweden. Dr Svanberg initially joined Serono International in 2000, where she held roles of increasing responsibilities prior to joining BMS and subsequently JNJ based in the US. Since 2016 she has served as Chief Development Officer at Ixaltis SA and since 2020 as Chief Medical Officer at Kuste Biopharma, two French startup companies. Over her career, Elisabeth has successfully developed products in different therapeutic areas.  She currently serves as member of the Board of Directors at Amolyt SA, Egetis Therapeutics AB , Galapagos SA and LEO Pharma.

Elisabeth adds extensive experience from her international pharma and biotech professional career, which will be of great value for EPICS Therapeutics in developing innovative new treatments in oncology. I am happy to have Elisabeth on board and I am looking forward to work with her on the future of EPICS Therapeutics, said Michel Alle, chairman of the Board of Directors.

EPICS Therapeutics with its excellent and experienced team of scientists is an exciting young company with the potential to change the treatment paradigm in oncology said Elisabeth Svanberg.

About EPICS Therapeutics

EPICS Therapeutics is a clinical stage Belgian, private, drug discovery and development company that invents and develops small molecule drugs targeting RNA epigenetic involved in cancer development. By targeting these mechanisms, Epics Therapeutics aims to translate science into life-changing therapies for patients.